Brian Richman, DPM
Podiatrist · Layton, UTNPI 1831124247
Payments from drug & device makers
What this record shows
Paragon 28, Inc. accounts for 65.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $1,725 and has fallen 87.9% since, to $209 in 2025.
Across 31 payments — averaging $81.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragon 28, Inc.$2K
- Sanara Medtech Inc.$248
- Boston Scientific$97
- Medtronic$56
- Smith+Nephew$53
- Vertex$52
- plus $368 from 13 others
What the payments were for
- Travel & lodging$1,15546%
- Food & beverage$1,37054%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragon 28, Inc. | 3 | $1,649 |
| Sanara Medtech Inc. | 1 | $248 |
| Boston Scientific | 3 | $97 |
| Medtronic | 1 | $56 |
| Smith+Nephew | 3 | $53 |
| Vertex | 3 | $52 |
| Averitas Pharma Inc. | 2 | $48 |
| Anika Therapeutics, Inc. | 1 | $42 |
| Solventum Corporation | 1 | $38 |
| Stryker | 2 | $38 |
| AbbVie(2 entities) | 2 | $32 |
| Treace Medical Concepts, Inc. | 2 | $28 |
| Globus Medical | 1 | $26 |
| 3M Company | 1 | $23 |
| Organogenesis Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Linvatec Corporation | 1 | $18 |
| Amgen | 1 | $15 |
| Biocomposites Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product Portfolio$1,649
- CellerateRx$248
How this compares
$2,525 in reported general payments places this provider in the 70th percentile of 59 podiatrist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pentoxifylline | 13 | $832 |
| Naproxen | 11 | $133 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $81 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Layton
- Jason BruseLayton$203K
- Brooks PotterLayton$3K
- Todd FlittonLayton$238
- Anna HronekSalt Lake City$82K
- Michele CarrDraper$56K
- David GraffOgden$39K
- Clark LarsenMurray$16K
- Kelly HamblinWest Jordan$13K
- Mikol AndersonSalt Lake City$9K
- Thomas EddyMurray$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.